Vertex Pharmaceuticals Incorporated
US ˙ NasdaqGS ˙ US92532F1003

SecurityVRTX / Vertex Pharmaceuticals Incorporated
InstitutionRichardson Financial Services Inc.
Latest Disclosed Ownership877 shares
Latest Disclosed Value $ 391,620
Richardson Financial Services Inc. reports 7.88% decrease in ownership of VRTX / Vertex Pharmaceuticals Incorporated

On May 1, 2026 - Richardson Financial Services Inc. filed a 13F-HR form disclosing ownership of 877 shares of Vertex Pharmaceuticals Incorporated (US:VRTX) valued at $391,616 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 22, 2026 disclosing 952 shares of Vertex Pharmaceuticals Incorporated. This represents a change in shares of -7.88% during the quarter. The current value of the position is $391,870 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-01 2026-03-31 13F VERTEX PHARMS COMMON STOCKS 92532F100 877 -75 -7.88 392 -9.28 0.1050
2026-01-22 2025-12-31 13F VERTEX PHARMS COMMON STOCKS 92532F100 952 10 1.06 432 17.12 0.1395
2025-10-28 2025-09-30 13F VERTEX PHARMS COMMON STOCKS 92532F100 942 -78 -7.65 369 -20.17 0.2287
2025-07-25 2025-06-30 13F Vertex Pharmaceuticals Common Stock 92532F100 1,020 6 0.59 461 -6.11 0.3098
2025-05-06 2025-03-31 13F Vertex Pharmaceuticals Common Stock 92532F100 1,014 40 4.11 492 26.55 0.3742
2025-01-24 2024-12-31 13F Vertex Pharmaceuticals Common Stock 92532F100 974 8 0.83 389 -14.16 0.2734
2024-10-24 2024-09-30 13F Vertex Pharmaceuticals Common Stock 92532F100 966 4 0.42 453 0.44 0.2877
2024-08-12 2024-06-30 13F Vertex Pharmaceuticals Common Stock 92532F100 962 25 2.67 451 15.09 0.3247
2024-05-03 2024-03-31 13F Vertex Pharmaceuticals Common Stock 92532F100 937 340 56.95 392 61.57 0.2760
2024-03-04 2023-12-31 13F VERTEX PHARMS COMMON STOCKS 92532F100 597 597 243 0.2128
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.